Fabrazyme (Agalsidase Beta)

Fabrazyme (Agalsidase Beta) is an enzyme replacement therapy used to manage Fabry disease. This intravenous medication helps address enzyme deficiencies, supporting metabolic function. Learn more about Fabrazyme's role in enzyme therapy.

Fabrazyme is primarily used in the treatment of Fabry disease, a genetic disorder caused by a deficiency in the enzyme alpha-galactosidase A. This medication helps to replace the missing enzyme, aiding in the breakdown of certain fats in the body. Fabrazyme is indicated for patients with Fabry disease to manage symptoms and improve overall metabolic function.

Common effects of Fabrazyme may include infusion-related reactions such as chills, fever, and fatigue. Some patients may also experience headaches or nausea. These effects are generally mild to moderate and may vary among individuals.

Fabrazyme should be administered under medical supervision, typically in a clinical setting. Patients should be monitored for any signs of infusion-related reactions. It is important to inform healthcare providers about any existing medical conditions or allergies before starting Fabrazyme therapy.

Fabrazyme may interact with certain medications, particularly those that affect the immune system or blood pressure. Patients should discuss all current medications with their healthcare provider to avoid potential interactions. Alcohol consumption should be moderated, as it may exacerbate certain side effects.